Navigation Links
Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
Date:9/24/2009

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that research led by Prof. Hardev Pandha of the Royal Surrey County Hospital, U.K., was published September 22, 2009 in the online version of Clinical Cancer Research. The paper is entitled "Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma."

The research demonstrated that the innate cancer killing activity of reovirus can be enhanced with a variety of commonly available therapeutic agents in models of malignant melanoma. Further, this work demonstrated that the combination of reovirus with cisplatin had the ability to nearly abrogate the production of inflammatory cytokines by the tumor cells, which is believed to augment virus replication in the tumor and improve its anti-cancer activity.

"These results provide further rationale for the Phase 2 drug combination study in patients with metastatic melanoma that was initiated today," said Dr. Matt Coffey, Chief Operating Officer of Oncolytics. "The results further support the strategic direction of enhancing oncolytic virus killing by combining REOLYSIN(R) with standard chemotherapeutic agents, notably paclitaxel and carboplatin. It is clear that these drug combinations provide multiple mechanisms of enhancing the innate cancer killing characteristics of our agent."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics,
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... , , , Multiporator , , , , , , ... Transfection Protocol , Protocol No. 4308 915.044 11/2001 , , ... , , Cell line , ... B, C negative, , MHC class II positive, , ...
... , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.043 11/2001 , ... , , , , ... MHC class II negative, , ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. ... , , , , , , ... , , Cell type , ...
Cached Biology Technology:721.221 2721.174 2721.174 3Saccharomyces cerevisiae 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... fall and rise to the beat of our internal drumsthe ... feeding patterns to the energy available to our cells. Whereas ... the pacemakers in peripheral organs are set by food availability. ... at the Salk Institute for Biological Studies shed light on ...
... ANN ARBOR, Mich.---Standing out in a crowd is better ... wasp in a colony where fights between nest-mates determine ... by University of Michigan researchers published online this week ... to be different, to wear a nametag advertising your ...
... increased risk of long-term illness, not because of the ... to a study in the urology journal BJUI ... Hospital at the University of Oslo found that the ... generally thought, because clinicians only report those that are ...
Cached Biology News:The food-energy cellular connection revealed 2The food-energy cellular connection revealed 3Being a standout has its benefits, study shows 2Treatment not testicular cancer poses greatest risk to survivors' long-term health 2Treatment not testicular cancer poses greatest risk to survivors' long-term health 3
...
... The Ultra Agarose Spin Kit is an advanced ... filters. The purified DNA can be used directly for ... fast protocol: DNA is ready to use in 56 ... Can be used for TAE and TBE gels ...
... The GenElute™ Minus EtBr Spin Columns provide ... bromide (EtBr)-free DNA (100 bp to 10 ... solutions. The DNA band is excised from an ... Embedded within the base of the column are ...
... designed for recovery of DNA from TAE and TBE ... Ultra fast protocol: DNA is ready to use in ... resuspend Bead uniformity prevents shearing of high molecular ... DNA is eluted into sterile water or TE ...
Biology Products: